ArticleNeuropsychiatric disease and treatment2025
High Prevalence and Clinical Correlates of Sarcopenia and Metabolic Syndrome in Outpatients with Major Depressive Disorder: A Cross-Sectional Study.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The relationships between Life's Crucial 9, Life's Essential 8, and sarcopenia in older adults: multicenter case-control study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the percentages, clinical characteristics, and risk factors of sarcopenia and metabolic syndrome (MetS) among outpatients with major depressive disorder (MDD). Methods: This study enrolled 225 MDD outpatients based on DSM-V and age- and sex-matched health controls (HCs). Sarcopenia was diagnosed based on the 2019 Asian Working Group for Sarcopenia diagnostic criteria. Three psychometric scales and the Montreal Cognitive Assessment were used to evaluate the severities of depression, anxiety, and somatic symptoms and cognitive function, respectively. Binary logistic regression models were used to investigate the risk factors of the two disorders. Results: MDD subjects had significantly higher percentages of sarcopenia (41.3% vs 15.6%), MetS (40.9% vs 28.9%), and sarcopenia and/or MetS (68.9% vs 40.4%) than HCs. For elderly MDD subjects, 89.3% suffered from sarcopenia and/or MetS. MDD subjects had higher unqualified percentages in handgrip strength and three physical performance tests than HCs. MDD subjects with sarcopenia had worse depression than those without. MDD subjects with MetS had poorer cognitive function than those without. MDD subjects with only sarcopenia had worse mood symptoms than those with only MetS. After controlling for age and other variables, full remission of depression decreased the risk of sarcopenia. Being overweight decreased and increased the risk of sarcopenia and MetS, respectively. Conclusions: Most MDD outpatients, especially elderly outpatients, suffered from sarcopenia and/or MetS. The two disorders should be screened in MDD patients. Treatment of depression might decrease the risk of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.